Cabaletta Bio (NASDAQ:CABA) Price Target Lowered to $3.00 at Wells Fargo & Company

Posted by Stanley Muller on Aug 14th, 2026

Cabaletta Bio (NASDAQ:CABA – Get Free Report) had its price target dropped by investment analysts at Wells Fargo & Company from $4.00 to $3.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 12.57% from the stock’s previous close.

Several other analysts have also recently commented on CABA. Wall Street Zen downgraded shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Jefferies Financial Group reiterated a “buy” rating on shares of Cabaletta Bio in a research report on Wednesday, June 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price target on shares of Cabaletta Bio in a research note on Monday, May 4th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cabaletta Bio presently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Read Our Latest Analysis on CABA

Cabaletta Bio Stock Down 1.7%

Shares of CABA stock traded down $0.04 on Friday, hitting $2.67. The stock had a trading volume of 902,177 shares, compared to its average volume of 3,697,239. Cabaletta Bio has a one year low of $1.40 and a one year high of $4.23. The business has a 50 day moving average price of $2.90 and a 200 day moving average price of $3.06. The company has a market cap of $434.53 million, a PE ratio of -1.35 and a beta of 3.30.

Cabaletta Bio (NASDAQ:CABA – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.03. Equities research analysts expect that Cabaletta Bio will post -1.38 EPS for the current year.

Institutional Trading of Cabaletta Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC purchased a new position in Cabaletta Bio in the 2nd quarter valued at $61,000. Quantbot Technologies LP acquired a new stake in shares of Cabaletta Bio in the 2nd quarter worth approximately $116,000. Callan Family Office LLC acquired a new position in Cabaletta Bio during the second quarter worth $54,000. Blue Owl Capital Holdings LP acquired a new position in shares of Cabaletta Bio during the 2nd quarter worth $2,223,000. Finally, E Fund Management Co. Ltd. purchased a new position in Cabaletta Bio during the 2nd quarter valued at about $64,000.

About Cabaletta Bio

(Get Free Report)

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.